|
Arix Bioscience PLC (ARIX)
14-Jun-2021 / 14:55 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Arix Bioscience Plc
Results of Annual General Meeting
LONDON, 14 June 2021: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or the "Company"), a global venture capital company focused on investing and building breakthrough biotech companies, today announces that its Annual General Meeting (the "Meeting") was held today, Monday, 14 June 2021, at 14.00 BST. At the Meeting, the ordinary and special resolutions set out in the Notice of the Annual General Meeting dated 18 May 2021 (the "Notice of AGM"), were proposed and passed by way of a poll. Resolutions 1 to 10 were passed as ordinary resolutions. Resolutions 11 to 14 were passed as special resolutions.
Full details of the poll results are set out below and will also be available on the Company's website.
|
No
|
RESOLUTION
|
VOTES FOR
|
%
|
VOTES AGAINST
|
%
|
TOTAL VOTES
|
% of ISC VOTED
|
VOTES WITHHELD
|
|
1
|
To receive the Directors' Report and the accounts of the Company for the year ended 31 December 2020
|
61,517,202
|
92.76%
|
4,800,657
|
7.24%
|
66,317,859
|
50.32
|
2,783
|
|
2
|
To approve the Directors' Remuneration Report
|
58,196,535
|
92.34%
|
4,825,953
|
7.66%
|
63,022,488
|
47.82
|
3,298,154
|
|
3
|
To re-elect Giles Kerr as a Director
|
61,344,286
|
92.51%
|
4,964,902
|
7.49%
|
66,309,188
|
50.31
|
11,454
|
|
4
|
To elect Peregrine Moncreiffe as a Director
|
60,271,773
|
92.55%
|
4,855,144
|
7.45%
|
65,126,917
|
49.42
|
1,193,725
|
|
5
|
To elect Maureen O'Connell as a Director
|
58,841,750
|
90.36%
|
6,274,013
|
9.64%
|
65,115,763
|
49.41
|
1,204,879
|
|
6
|
To elect Isaac Kohlberg as a Director
|
58,842,050
|
90.35%
|
6,285,167
|
9.65%
|
65,127,217
|
49.42
|
1,193,425
|
|
7
|
To elect Robert Lyne as a Director
|
60,072,787
|
90.59%
|
6,236,701
|
9.41%
|
66,309,488
|
50.31
|
11,154
|
|
8
|
To appoint BDO LLP as auditors of the Company
|
61,500,167
|
92.74%
|
4,817,701
|
7.26%
|
66,317,868
|
50.32
|
2,774
|
|
9
|
To authorise the Audit and Risk Committee of the Company to fix the remuneration of the auditors
|
61,516,153
|
92.76%
|
4,804,189
|
7.24%
|
66,320,342
|
50.32
|
300
|
|
10
|
To authorise the Directors to allot shares
|
61,019,094
|
92.01%
|
5,297,239
|
7.99%
|
66,316,333
|
50.32
|
4,309
|
|
11
|
Authority to disapply statutory pre‐ emption rights*
|
59,364,402
|
89.52%
|
6,951,931
|
10.48%
|
66,316,333
|
50.32
|
4,309
|
|
12
|
Additional authority to disapply statutory pre‐ emption rights*
|
59,363,555
|
89.52%
|
6,952,778
|
10.48%
|
66,316,333
|
50.32
|
4,309
|
|
13
|
To authorise the Company to purchase its own shares*
|
61,478,596
|
92.71%
|
4,836,857
|
7.29%
|
66,315,453
|
50.32
|
5,189
|
|
14
|
Authority to call a general meeting, other than an annual general meeting, on not less than 14 clear days' notice*
|
61,517,295
|
92.76%
|
4,803,047
|
7.24%
|
66,320,342
|
50.32
|
300
|
*Special resolutions
In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting concerning items other than ordinary business will shortly be available for inspection on the National Storage Mechanism, which can be accessed at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The full text of the resolutions considered at the AGM are contained in the Notice of AGM, published on 18 May 2021, which is available on Arix investor relations website.
A replay of the presentation and the Meeting will be available via webcast shortly after the event on the Company's investor relations website at: https://arixbioscience.com/investor-relations/events-presentations
[ENDS]
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor Relations
+44 (0)20 7290 1072
charlotte@arixbioscience.com
Optimum Strategic Communications
Mary Clark, Supriya Mathur, Shabnam Bashir
+44 (0)20 3922 1906
optimum.arix@optimumcomms.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
|
